Dr. Falk Pharma
Open enrollment with a later-stage pipeline tilt
According to ClinicalTrials.gov-derived indexes, Dr. Falk Pharma sits in the upper quartile of US sponsors by registered trial count (#3,661 of 15,742 sponsors by registered trial count).
Dr. Falk Pharma: 3 sponsored US clinical trials, 2 recruiting.
Dr. Falk Pharma sponsors 3 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting. 2 of these trials are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Eosinophilic Esophagitis, with 1 trials.
Upper-quartile sponsor footprint
Dr. Falk Pharma sits in the upper quartile of the sponsor corpus (#3,661 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
3 total, page 1 of 1
Different Doses of Naronapride Vs. Placebo in Gastroparesis
NCT05621811
Once Daily Versus Twice Daily Budesonide Orodispersible Tablets for Induction of Remission in EoE
NCT06596252
Two Doses Mesalazine Granules Versus Placebo for the Prevention of Recurrence of Diverticulitis
NCT01038739
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 1 |
| Phase 3 | 2 |
Therapeutic Areas
Where Dr. Falk Pharma enrollment is open (later-stage tilt)
2 recruiting of 3 indexed (67% open).
Phase mix: 2 late (III/IV) vs 1 early (I/II) (later-stage heavy).
Top condition: Eosinophilic Esophagitis (1 trial), 1 other listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Dr. Falk Pharma: open-pipeline peers nationwide
Peers matched on 3 registered trials and 67% open enrollment, not the therapeutic-area sidebar.
Dr. Falk Pharma sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 3 trials (± recruiting share)
- 10xBio · 3 trials · 0% recruiting
- 22nd Century Group · 3 trials · 0% recruiting
- AA Secord · 3 trials · 0% recruiting
- AAADRS Clinical Research Center · 3 trials · 0% recruiting
Sponsors near 67% open enrollment (± trial volume)
- Abbisko Therapeutics Co · 67% recruiting · 6 trials
- ABL Bio · 67% recruiting · 3 trials
- Accelerated Cure Project for Multiple Sclerosis · 67% recruiting · 3 trials
- Advanced Reconstructive Surgery Alliance · 67% recruiting · 3 trials
Related
What to do with this Dr. Falk Pharma page
3 registered trials is a research-attention snapshot, not an endorsement of Dr. Falk Pharma or any single study.
- 2 of Dr. Falk Pharma's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Eosinophilic Esophagitis is the condition Dr. Falk Pharma studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Eosinophilic Esophagitis trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Dr. Falk Pharma pipeline card: 3 registered trials from official public datasets.Report a data error.